PR84011

DAEJEON, South Korea, May 15, 2020 /PRNewswire=KYODO JBN/ --

-       STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's

proprietary drug discovery artificial intelligence solution, demonstrated

powerful immuno-oncologic effect.

-       Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint

inhibitors (ICIs) presented complete remission (CR) of tumor and long-term

survival benefit.

-       Subsequent nonclinical development and collaborative efforts might

yield IND submission within 2 years

Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company,

presented the result of STB-C017 animal experiments, a small molecule IDO/TDO

dual inhibitor derived by Syntekabio's AI drug discovery solution, at the 2020

American Association for Cancer Research (AACR) Annual Meeting, today at 00:00

EDT.

Photo - https://photos.prnasia.com/prnh/20200512/2801418-1

The triple combination of STB-C017, aPD-1 and aCTLA-4 prolongs overall survival

Chan Kim, M.D., Ph.D., associate professor of CHA Bundang Medical Center and

the presenter of the research, stated, "STB-C017 significantly enhanced

immuno-oncologic effect compared to epacadostat. It also derived multiple CRs

when combined with ICIs." Hong Jae Chon, M.D., Ph.D., the principal

investigator, said, "Specifically in renal cell carcinoma, hepatocellular

carcinoma, anti-PD-1/CTLA-4 combination is becoming standard-of-care, so

combining STB-C017 on top of those combination could yield impressive treatment

enhancement."

"The result showed significant feasibility of subsequent development for

STB-C017. When the STB-C017 reach market, those ICIs would be used more

broadly, which would give us the opportunity," said Sunil Youn, M.D., Business

Development Director of Syntekabio.

The presentation with key findings is titled "Artificial intelligence with a

deep learning technology enables a rational development of a potent

immunotherapeutic agent" and includes:

1. STB-C017 effectively blocked kynurenine secretion from tumor, an

immunosuppressor, and showed dose-response relationship in colorectal cancer

mice models.

2. STB-C017 treatment showed significant infiltrations of CD8+ T cells into the

tumor, and reduction of Treg Cells.

3. STB-C017 dosing regimen optimized as 5 days of administration & 2 days off

Combination therapy with anti-PD1/CTLA4 markedly delayed tumor growth and

induced multiple CRs.

- STB-C017 triple combination induced two-fold increase of CRs compared to

epacadostat triple. Recovered mice acquired long-term antineoplastic immunity.

- Mice treated with STB-C017 triple combination showed marked survival benefit

compared to the others, including epacadostat triple.

Syntekabio plans subsequent STB-C017 development, including GLP toxicology and

animal PKPD, targeting IND submission, around 1H 2022. The company will execute

further translational research based on firm collaboration with CHA Bundang

Hospital and lead the full scope of the development programs.

SOURCE: Syntekabio, Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=363472

   Caption: The triple combination of STB-C017, aPD-1 and aCTLA-4 prolongs overall survival